The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes

Annals of Hematology

Volumn 92, Issue 10, 2013, Pages 1335-1343

  Fu, Bin ^a,b   Ok, Chi Young ^a   Goswami, Maitrayee ^a   Xei, Wei ^a   Jaso, Jesse M ^a   Muzzafar, Tariq ^a   Bueso Ramos, Carlos ^a   Verstovsek, Srdan ^a   Garcia Manero, Guillermo ^a   Medeiros, L Jeffrey ^a   Wang, Sa A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

AML transformation; Bone marrow fibrosis; Cytogenetics; Overall survival; Therapy related myelodysplastic syndromes

Indexed keywords

CYTOTOXIC AGENT; EOSIN; GROWTH FACTOR; HEMATOXYLIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; REAGENT; RETICULIN; TRICHROME; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; CANCER RISK; CELL COUNT; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MUTATOR GENE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; THERAPY RELATED MYELODYSPLASTIC SYNDROME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PRIMARY MYELOFIBROSIS; PROTO-ONCOGENE PROTEINS C-KIT; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84883883010     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1776-3     Document Type: Article

References (36)

1. Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, Leder LD, Schaefer HE (2001) Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol 19(12):2994-3009
2. Subramanian R, Basu D, Dutta TK (2007) Significance of bone marrow fibrosis in multiple myeloma. Pathology 39(5):512-515. doi: 10.1080/ 00313020701570038
3. Thiele J, Kvasnicka HM (2005) Hematopathologic findings in chronic idiopathic myelofibrosis. Semin Oncol 32(4):380-394. doi: 10.1053/j.seminoncol. 2005.04.010
4. Thiele J, Kvasnicka HM (2006) Grade of bone marrow fibrosis is associated with relevant hematological findings - a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 85(4):226-232. doi: 10.1007/s00277-005-0042-8
5. Vener C, Fracchiolla NS, Gianelli U, Calori R, Radaelli F, Iurlo A, Caberlon S, Gerli G, Boiocchi L, Deliliers GL (2008) Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 111(4):1862-1865. doi: 10.1182/blood-2007-09-112953
6. Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, Savi F, Moro A, Grifoni F, De Philippis C, Radice T, Bosari S, Lambertenghi Deliliers G, Cortelezzi A (2012) The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Modern pathology 25(9):1193-1202. doi: 10.1038/modpathol.2012.87
7. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937-951. doi: 10.1182/blood-2009-03-209262
8. Verhoef GE, De Wolf-Peeters C, Ferrant A, Deprez S, Meeus P, Stul M, Zachee P, Cassiman JJ, Van den Berghe H, Boogaerts MA (1991) Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 63(5):235-241
9. Della Porta MG, Malcovati L (2011) Myelodysplastic syndromes with bone marrow fibrosis. Haematologica 96(2):180-183. doi: 10.3324/haematol.2010.039875
10. Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, Gohring G, Schlegelberger B, Bock O, Georgii A, Kreipe H (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22(2):313-322. doi: 10.1038/sj.leu.2405030
11. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27(5):754-762. doi: 10.1200/JCO.2008.18.2246
12. Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T (2011) Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica 96(2):291-297. doi: 10.3324/haematol.2010.031229
13. Voso MT, D'Alo F, Greco M, Fabiani E, Criscuolo M, Migliara G, Pagano L, Fianchi L, Guidi F, Hohaus S, Leone G (2010) Epigenetic changes in therapy-related MDS/AML. Chemico-biological interactions 184(1-2):46-49. doi: 10.1016/j.cbi.2009.10.013
14. Greco M, D'Alo F, Scardocci A, Criscuolo M, Fabiani E, Guidi F, Di Ruscio A, Migliara G, Pagano L, Fianchi L, Chiusolo P, Hohaus S, Leone G, Voso MT (2010) Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood cells, molecules & diseases 45(3):181-185. doi: 10.1016/j.bcmd.2010.05.008
15. Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M, McDonald T, Gyorffy J, Chang K, Wang S, Fan W, Li J, Zhao LP, Radich J, Forman S, Bhatia S, Bhatia R (2011) Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer cell 20(5):591-605. doi: 10.1016/j.ccr.2011.09.011
16. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J (2005) Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 19(12):2232-2240. doi: 10.1038/sj.leu.2404009
17. Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, Larson RA, Vardiman JW (2007) Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 127(2):197-205. doi: 10.1309/NQ3PMV4U8YV39JWJ
18. Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I, Thiele J (eds) (2008) Therapy-related myeloid neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC), vol 184, 4th edn. Elsevier, Lyon, pp 16-20
19. Klyuchnikov E, Holler E, Bornhauser M, Kobbe G, Nagler A, Shimoni A, Konecke C, Wolschke C, Bacher U, Zander AR, Kroger N (2012) Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol. doi: 10.1111/bjh.12013
20. Quintas-Cardama AKH, Shan J, Jabbour E, Faderl S, Wierda WG, RavandiF KT, Wang SA, Pierce S, Kantarjian HM, Garcia-Manero G (2012) A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Blood 118(suppl 1):967
21. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):1128-1132
22. Khoury JD, Sen F, Abruzzo LV, Hayes K, Glassman A, Medeiros LJ (2003) Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol 34(10):1022-1029
23. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454-2465. doi: 10.1182/blood-2012-03- 420489
24. Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstocker M, Nosslinger T, Valent P, Giagounidis A, Aul C, Lubbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30(8):820-829. doi: 10.1200/JCO.2011.35.6394
25. Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE (2009) Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer 115(23):5481-5489. doi: 10.1002/cncr.24610
26. Millecker L, Lennon PA, Verstovsek S, Barkoh B, Galbincea J, Hu P, Chen SS, Jones D (2010) Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations. Cancer genetics and cytogenetics 197(1):1-7. doi: 10.1016/j.cancergencyto.2009. 10.014
27. Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ, Wang SA (2009) Therapy-related acute myeloid leukemia with t (8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t (8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 131(5):647-655. doi: 10.1309/AJCP5ETHDXO6NCGZ
28. Tefferi A (2005) Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 23(33):8520-8530. doi: 10.1200/JCO.2004.00.9316
29. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC (2012) Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 118(11):2879-2888. doi: 10.1002/cncr.26537
30. Hussein K, Van Dyke DL, Tefferi A (2009) Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol 82(5):329-338. doi: 10.1111/j.1600-0609.2009.01224.x
31. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105(3):973-977. doi: 10.1182/blood-2004-07-2864
32. Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110(12):4030-4036. doi: 10.1182/blood-2007-07-099184
33. Klimek VM, Dolezal EK, Tees MT, Devlin SM, Stein K, Romero A, Nimer SD (2012) Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leuk Res 36(9):1093-1097. doi: 10.1016/j.leukres.2012.04.025
34. Breccia M, Salaroli A, Loglisci G, Martelli M, D'Elia GM, Nanni M, Mauro FR, Alimena G (2011) 5′-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment. Leuk Res 35(10):1409-1411. doi: 10.1016/j.leukres.2011.05.030
35. Buhr T, Busche G, Choritz H, Langer F, Kreipe H (2003) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 119(1):152-158. doi: 10.1309/PTVG-B3DX-B8A8-M7KD
36. Morel F, Le Bris MJ, Herry A, Morice P, De Braekeleer M (2003) Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature. Leukemia & lymphoma 44(3):549-551. doi: 10.1080/1042819021000055084